日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment

质子泵抑制剂联合帕博西尼或阿贝西利治疗内分泌敏感性乳腺癌

Takada, Shinya; Takahashi, Kaori; Uozumi, Ryuji; Mukohara, Toru; Hayashida, Tetsu; Iwabe, Midori; Iihara, Hirotoshi; Kusuhara-Mamishin, Kanako; Tahatsu, Kanae; Kitagawa, Yuko; Tsuchiya, Masami; Kitahora, Mika; Umehara, Kengo; Nagayama, Aiko; Kosaka, Shinkichi; Asano-Niwa, Yoshimi; Watanabe, Kenichi; Seki, Tomoko; Ohnuki, Koji; Futamura, Manabu; Kawazoe, Hitoshi; Nakamura, Tomonori

Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC

EGFR突变型不可切除III期非小细胞肺癌同步放化疗的临床疗效和安全性

Takamori, Shinkichi; Shimokawa, Toshio; Osoegawa, Atsushi; Abe, Miyuki; Takumi, Yohei; Sugawara, Shunichi; Niho, Seiji; Goto, Yasushi; Okamoto, Hiroaki; Hotta, Katsuyuki; Ozawa, Yuichi; Oizumi, Satoshi; Yamamoto, Nobuyuki; Mitsudomi, Tetsuya; Yamaguchi, Masafumi

Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis

接受新辅助纳武利尤单抗联合化疗的可切除非小细胞肺癌患者术前免疫相关不良事件:一项多中心回顾性分析

Watanabe, Takuya; Nomura, Kotaro; Takamori, Shinkichi; Tane, Shinya; Ohara, Shuta; Oiki, Hana; Katsumata, Shinya; Endo, Makoto; Takamori, Satoshi; Nakatsuka, Marina; Tenpaku, Hironori; Nakamura, Ryuji; Notsuda, Hirotsugu; Namba, Kei; Minegishi, Kentaro; Tanahashi, Masayuki; Tsuboi, Masahiro; Soh, Junichi; Shimokawa, Mototsugu; Ohde, Yasuhisa

Osteocytes regulate osteoprotegerin expression via the p38-MAPK-CREB pathway in rheumatoid arthritis.

在类风湿性关节炎中,骨细胞通过 p38-MAPK-CREB 通路调节骨保护素的表达。

Yasumoto Keitaro, Fujiwara Toshifumi, Sugita Toshiaki, Arisumi Shinkichi, Kawamura Shotaro, Utsunomiya Takeshi, Hara Daisuke, Kawahara Shinya, Yamaguchi Ryosuke, Akasaki Yukio, Hamai Satoshi, Motomura Goro, Yamada Hisakata, Nakashima Yasuharu

Correction: A nationwide questionnaire survey to investigate facility‑based disparities in satisfaction and working conditions of surgical trainees in Japan: university hospitals, community hospitals, and hybrid‑type facilities

更正:一项针对日本外科住院医师满意度和工作条件的全国性问卷调查,旨在调查不同医疗机构(包括大学附属医院、社区医院和混合型医疗机构)之间的差异。

Koike, Daisuke; Takagi, Kosei; Arai, Keisuke; Kiyasu, Yoshiyuki; Kohmura, Takashi; Suda, Chiaki; Takamori, Shinkichi; Takayama, Wataru; Nakamura, Mai; Fukumoto, Masayuki; Yamaoka-Fujikawa, Yoshiko; Watanabe, Genki; Watanabe, Jun; Poudel, Saseem; Ikeda, Norihiko; Taketomi, Akinobu; Saito, Mitsue

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

MUCIN 1 赋予非小细胞肺癌对酪氨酸激酶抑制剂耐药性的炎症记忆。

Takamori Shinkichi, Haratake Naoki, Bhattacharya Atrayee, Kikutake Chie, Ozawa Hiroki, Shigeta Keisuke, Nakashoji Ayako, Isozaki Hideko, Shimokawa Mototsugu, Suyama Mikita, Hashinokuchi Asato, Takada Kazuki, Toyokawa Gouji, Yamada Yuichi, Takenaka Tomoyoshi, Taguchi Kenichi, Yamaguchi Masafumi, Yoshizumi Tomoharu, Hata Aaron N, Kufe Donald

Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.

在非小细胞肺癌细胞中,MUC1-C 整合了 APOBEC3 胞苷脱氨酶和内源性逆转录病毒的激活

Haratake Naoki, Takamori Shinkichi, Isozaki Hideko, Shigeta Keisuke, Kikutake Chie, Ozawa Hiroki, Bhattacharya Atrayee, Nakashoji Ayako, Suyama Mikita, Takenaka Tomoyoshi, Yoshizumi Tomoharu, Osoegawa Atsushi, Hata Aaron N, Kufe Donald

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy.

MUC1-C 在耐药性前列腺癌中的依赖性揭示了抗体药物偶联疗法的靶点

Shigeta Keisuke, Daimon Tatsuaki, Hongo Hiroshi, Ku Sheng-Yu, Ozawa Hiroki, Haratake Naoki, Fushimi Atsushi, Nakashoji Ayako, Bhattacharya Atrayee, Takamori Shinkichi, Kono Michihisa, Rokugo Masahiro, Baba Yuto, Kosaka Takeo, Oya Mototsugu, Jacobi Justine, Long Mark D, Beltran Himisha, Kufe Donald

Comprehensive characterization of human alveolar epithelial cells cultured for 28 days at the air-liquid interface.

对在气液界面培养 28 天的人类肺泡上皮细胞进行全面表征

Tanabe Ikuya, Ishikawa Shinkichi

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer

免疫疗法联合辅助放化疗治疗病理分期为II-IIIB期的非小细胞肺癌未显示出生存获益

Venugopal, Natasha; Vazquez-Urrutia, Jorge Raul; Zhu, Junjia; Hashinokuchi, Asato; Takamori, Shinkichi; Komiya, Takefumi